SEC Tracker
Get the app

Avalo Therapeutics AVTX

Avalo Therapeutics Q2 FY25: net loss $20.8M; diluted EPS −$1.92

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Avalo Therapeutics reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$20.8M−121% from $98.5M in Q2 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$1.92Against −$14.07 in Q2 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$42.3M−55% from $93.4M in Q2 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$11.4MAgainst −$16.3M in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Avalo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2834) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. iBio IBIO public float $58M, Dec 31, 2025
  2. Opus Genetics IRD public float $46M, Jun 30, 2025
  3. Medicinova MNOV public float $62M, Jun 30, 2025
  4. Lifevantage LFVN public float $64M, Dec 31, 2025
  5. Actinium Pharmaceuticals ATNM public float $44M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.